Clinical Trials Logo

Renal Neoplasm With Metastasis clinical trials

View clinical trials related to Renal Neoplasm With Metastasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03616951 Recruiting - Clinical trials for Response Evaluation Criteria in Solid Tumors

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

The incidence of renal cancer in Denmark is approximately 900 new cases per year. Untreated, the 5-year survival rate for metastatic renal cancer (mRCC) is 2%. Development of angiogenesis inhibitors (AI) and check-point immunotherapy (CPI) has improved survival. Treatment efficacy is evaluated by CT scans, using RESIST 1.1 (Response Evaluation Criteria in Solid Tumors). However, progressin in patients with mRCC treated with AI or CPI is difficult to characterize at the right time, using the RECIST 1.1. Therefore approximately 50 % of the patients are 'lost' to further treatment at the time of progression and die. The investigators aim to evaluate if functional imaging parameters using spectral CT-techniques can detect treatment failure earlier, or more accurate, than routine CT. This could help us develop a new set of response evaluation criteria for functional imaging, giving a more precise assessment of treatment effect in patients with mRCC treated with AI and CPI.